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Some inhalers have been claimed to give better deposition, resulting in higher ecacy. In a previous study we did
not find any evidence of dierent potency of salbutamol given either via pMDI or Turbuhaler1. The aim of the
present study was to compare the ecacy and safety of salbutamol given via Diskus2 or Turbuhaler. Twenty-five
asthmatics with step-wise reversible airflow obstruction (total reversibility of at least 15%) were included in a
randomized, double-dummy, placebo-controlled cross-over study. On each study day, the patients were given
placebo repeatedly, or cumulative doses of 200, 400, 800, 1600 and 3200 mg salbutamol given via either device
(double-blind, placebo-controlled). Salbutamol caused a dose-related increase in FEV1 when given by Diskus or
Turbuhaler. The improvement in FEV1 was similar regardless of whether salbutamol was given via Diskus or
Turbuhaler, at equivalent microgram doses. After a total cumulative dose of 3200 mg, mean FEV1 for Diskus was
246 l (change from baseline of 205%), for Turbuhaler 250 l (change from baseline 246%) and for placebo 211 l
(3% change from baseline). After correcting for dierent baseline dierences, the percentage dierence between
Diskus and Turbuhaler was 718% (P=02). Systemic eects (potassium and heart rate) did not dier between
Diskus or Turbuhaler. We conclude that the ecacy of salbutamol given at equivalent microgram doses, as well as
side-eects, are comparable when the drug is given via Diskus or Turbuhaler. The present data shows that
salbutamol given by these devices have similar therapeutic ratios.
Key words: asthma; Salbutamol; inhalers; Turbuhaler1; Diskus2; lung.
RESPIR. MED. (2000) 94, 574–577 # 2000 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2000) 94, 574–577
doi:10.1053/rmed.1999.0778, available online at http://www.idealibrary.com onIntroduction
Salbutamol is a relative selective b2-receptor agonist, which
was developed in the 1960s and first marketed, in
pressurized metered dose inhalers (pMDI) for local airway
treatment. Since its introduction, extensive clinical studies
have established the ecacy and safety of salbutamol
delivered via the pMDI in the treatment of reversible
obstructive disease. The pMDI has become the most
popular and well-established way of delivering asthma
medications to the lung, available in more than 90
countries. The reasons for the popularity of the pMDI
have been its safety, portability, low cost and relative ease
of use.
Although experienced pMDI users find it relatively easy
to use, some patients do have diculty in co-ordinating
inspiration with inhalation, especially children and theReceived 15 June 1999 and accepted in revised form 21 December
1999.
Correspondence should be addressed to: P. Arvidsson, Lung
Pharmacology Group, Bruna stra˚ket 11, Dpt of Respiratory
Medicine and Allergology, Go¨teborg University, S-413 45 Gothen-
burg, Sweden.
0954-6111/00/060574+04 $35?00/0elderly. This problem can to some degree be overcome by
the use of spacers or breath-actuated powder inhalers.
Several dierent multiple dose powder inhalers have been
introduced, including Turbuhaler1, Diskhaler2 and
Diskus, all of which are more or less dependent upon the
patient achieving enough inspiratory eort to aerosolize the
powder. The short acting b2-agonist terbutaline, and
the corticosteroid budesonide, have been available in the
Turbuhaler for a number of years and clinical studies have
demonstrated equivalent, or even improved ecacy of these
two drugs when delivered via pMDI as compared with
Turbuhaler (1–5).
Most recently, salbutamol has become available in the
Turbuhaler. Some studies, comparing the ecacy and
safety of salbutamol given via Turbuhaler or pMDI have
been presented. One of these recent studies suggests that
when salbutamol is given via the Turbuhaler, only half the
dose is required compared to when the drug is given by the
pMDI (6). In contrast to this study, our group has recently
not been able to document any dierence in the bronch-
odilatory eect of salbutamol given either via Turbuhaler
or pMDI (7).
The Diskus is a new multiple powder inhaler, and clinical
studies have demonstrated equivalent ecacy and safety# 2000 HARCOURT PUBLISHERS LTD
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No data have been presented, comparing directly the safety
and ecacy of salbutamol given via the Diskus or
Turbuhaler.
The aim of the present study was to evaluate whether any
dierences in the topical or systemic eects of salbutamol
are evident when the drug is given as the same cumulative
doses via Diskus or Turbuhaler.
Patients and methods
The study was performed in accordance with the principles
stated in the Declaration of Helsinki, and was approved by
the Ethics Committee of Go¨teborg and the Swedish Drug
Agency (Uppsala, Sweden). Furthermore, Good Clinical
Trial Practice principles were applied, and the study was
monitored by the sponsor (Glaxo Wellcome).
PATIENTS
Twenty-five adult patients (13 women), non-smokers, all
with reversible airflow obstruction, were included. The
mean age was 54 years (31–71), mean height 171 cm, and
mean weight 72 kg. All patients were using inhaled
glucocorticoids regularly, and short-acting b2-agonists
p.r.n. (as needed). The patients were permitted to use
inhaled corticosteroids (up to 1000 mg b.d.), sodium
cromoglycate, nedocromil sodium and antihistamines,
provided that the dose was constant for 4 weeks prior to
visit 1 and remained constant during the trial.
Regarding b2-agonists, they were not allowed to take
long-acting b2-agonists for 12 h and short-acting for 6 h
prior to each clinic visit.
STUDY DESIGN
The study was designed as a randomized, double-blind,
double-dummy, cross-over study to measure the topical and
systemic eects in cumulative doses of salbutamol delivered
by the Turbuhaler compared with the Diskus inhaler.
Topical eects were assessed by measurement of FEV1 and
the systemic eects by serum potassium, heart rate, systolic
and diastolic blood pressure. The same equipment (Vitalo-
graph Compact, Vitalograph, Birmingham, U. K.) was
used at all four clinic visits. The device was calibrated every
morning. The highest of three technically acceptable
measurements of FEV1 was recorded in the Case Report
Form.
At the pre-study visit, eligibility was assessed, which
was followed 36 h–10 days later by three study visits
(spaced 36 h–10 days apart). Finally, a post-study check
was performed to complete the study.
At the pre-study screen, patients received 200 mg
salbutamol (given by pMDI, Ventoline) followed 30 min
later by 1600 mg salbutamol. The improvement seen should
be at least 10% 15 min after 200 mg salbutamol, followed
by another at least 50% increase of the eect observed after
the lower dose.The patients were not allowed to take an inhaled short-
acting b2-agonist 6 h, long-acting b2-agonist 12 h, or an
oral/sustained-release b2-agonist 24 h prior to pre-study
day, or on the three study days. Theofyllin, oral corticos-
teroids or leucotriene synthesis blockers/receptor antago-
nists were not permitted during the conduct of the study or
for the 4 weeks prior to visit 1.
On the three study days, each patient were given the
following treatments in a randomized order: (a) salbutamol
via Turbuhaler and placebo via Diskus or (b) salbutamol
via Diskus and placebo via Turbuhaler or (c) placebo via
Turbuhaler and Diskus.
Salbutamol was given in cumulative doses at approxi-
mately 30-min intervals (time=0, 30, 60, 90 and 120 min).
The doses were 200, 200, 400, 800 and 1600 mg, resulting in
cumulative doses of 200, 400, 800, 1600 and 3200 mg. The
nominal dose per actuation was 100 mg from the Turbu-
haler and 200 mg from the Diskus (2+2+4+8+16=32
inhalations via the Diskus and twice as many via the
Turbuhaler per day). During the placebo day, exactly the
same protocol was followed.
Blood samples for potassium was taken prior to the
cumulative design regimen (baseline). After that, blood
samples for potassium, blood pressure and FEV1 measure-
ments were taken 20–25 min after each cumulative dose.
Heart rate was measured by taking pulse at the level of
arteria radialis.
STATISTICAL METHODS
Pre-study power calculation gave an estimate that 24 patients
would give 80% power to show equivalence of the
treatments. Retrospective analysis show that the equivalence
region (95% confidence intervals) for any time point is
always within 0.12 l for FEV1. The data obtained 20 min
after each cumulative dose was averaged. The baseline value
obtained prior to dosing was used as the value for a zero
cumulative dose. Each of the variables (FEV1, heart rate and
plasma potassium) were summarized in three ways:
. the mean values obtained after cumulative dose;
. area under the response time curve;
. the slope from linear regression of the response against
cumulative dose of each treatment (logged data).
Comparison of mean values at nominal time points or
after specified cumulative doses was performed by analysis
of covariance using SAS proc GLM. The model included
terms for patient, visit (i.e. period), baseline (pre-dosing)
level, as well as treatment group. Estimates of the dierence
between treatments, Diskus vs. turbuhaler, Diskus vs.
placebo, Turbuhaler vs. placebo were calculated together
with 95% confidence intervals.
Comparison of mean area under the response-time curve
(AUC) and the mean slope of regression of response on
(log-) cumulative dose (slope) for each individual patient
were carried out using the same procedure as above, though
with a change of response variable (AUC or SLOPE) as
appropriate.
FIG. 2. Change in s-potassium (S-K+),(mmol71/l), after
cumulative doses of salbutamol given via Turbuhaler (~)
or Diskus (&), or placebo (*) by both devices at
corresponding time points. Data are shown as means.
BL = baseline. The maximum standard error for each
treatment was 008 for Turbuhaler, 007 for diskus and
005 for placebo.
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Twenty-five patients were included in the study and all
patients completed the study. Salbutamol given either by
Turbuhaler or Diskus caused significant and dose-related
improvement in FEV1 (Fig. 1). Mean FEV1 20 min after the
end of dosing (cumulative dose of 3200 mg), was 250 l with
Turbuhaler, 246 l with Diskus and 211 l with placebo.
These values correspond to a percentage change from
baseline of 246%, 205% and 32% with Turbuhaler,
Diskus and placebo respectively. After correction for
baseline (pre-dosing) dierences, the percentage dierence
between Diskus and Turbuhaler was 71.8% (P=02).
Comparing Diskus vs. placebo, the dierence was 163%
(P<0001) and when comparing Turbuhaler vs. placebo,
the dierence was 185% (P<0.001). The 95% confidence
intervals were747 to +18% for the comparison between
Diskus and Turbuhaler. Looking at all time points
throughout the observation period, the maximal 95%
confidence intervals between treatments are 55%, which
equates to a maximal treatment dierence of 012 l.
The average AUC dierence over the interval (t=0–
t=140; baseline to 3200 mg) between salbutamol Turbu-
haler and Diskus was calculated, and equalled to 7002 l
(CI:7009–005 l). Comparison of average regression slopes
over the dosing interval showed similar results (data not
shown). With salbutamol Turbuhaler, FEV1 increased by
007 l for each doubling dose, with salbutamol Diskus this
increase was 006 l, and on placebo 002 l. The dierence
between active treatments corrected for baseline dierences
was 0009 l per doubling dose.
There was no tendency for dierence in the induced
changes in S-potassium (Fig. 2), in heart rate (Fig. 3) orFIG. 1. FEV1 before and after cumulative doses of
salbutamol given via Turbuhaler (~) or Diskus (&), or
placebo (*) by both devices at corresponding time points.
Data are shown as means. BL = baseline. The maximum
standard error for each treatment was 016 for
Turbuhaler, 017 for diskus and 014 for placebo.diastolic blood pressure, and after total cumulative dosing,
these variable were all within the defined region for
equivalence comparing the two active treatments (95%
confidence intervals for the true dierence).
Discussion
In their eect on FEV1, this study clearly demonstrates the
equivalence of delivery of salbutamol in a doubling dose
schedule via either Turbuhaler or Diskus. In addition, it
demonstrates that both treatments show a marked benefitFIG. 3. Change in heart rate (beats min71) after
cumulative doses of salbutamol given via Turbuhaler (~)
or Diskus (&), or placebo (*) by both devices at
corresponding time points. Data are shown as means.
BL= baseline.
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meters, heart rate and plasma potassium, are similar with
either device.
The Turbuhaler has been suggested to improve lung
deposition of inhaled drugs vs. several other inhalers (1,8),
but no direct comparison of Turbuhaler versus Diskus has
been reported. This dierence in lung deposition has been
suggested to improve the ecacy of terbutaline and
budesonide given by the Turbuhaler vs. their corresponding
pMDI (1,4,5). Some studies have also argued that
salbutamol Turbuhaler is more ecacious than salbutamol
pMDI (6,10–12). However, one weakness of these studies is
that the drugs were not compared on equal mg doses. Also,
in the study by Lo¨fdahl (6), the observed dierences in
FEV1 between the lowest and highest dose of salbutamol
was quite small, amounting to a mean of 015 l suggesting a
quite shallow dose–response curve in the studied patients.
In a more recent study, we have been unable to detect any
numeric dierences in the improvement in FEV1 between
salbutamol given by the Turbuhaler and pMDI (7), which
others also have been unable to detect when evaluating
eects of salbutamol on methacholine responsiveness (9).
In the present study, we have been unable to detect any
dierences in potency of salbutamol given by Turbuhaler
vs. Diskus. Numerically, the dierences between the devices
amounted to approximately 004 l, in favour of the
Turbuhaler (D008 l), which is far from statistically
significant, and not likely to be of clinical importance.
Furthermore, no dierences in systemic side-eects were
detected, again arguing against clinical dierences in
deposition and systemic absorption of these drugs. This is
quite important, since the Turbuhaler has been suggested to
give more peripheral deposition, which hypothetically could
result in more prominent side-eects, because of more
systemic absorption from peripheral airways and lung
tissue. Thus, the improved peripheral deposition of
bronchodilators given by the Turbuhaler does not seem to
lead to improved clinical ecacy, and does not aect the
therapeutic ratio.
The dose response eect between the lowest and highest
dose of salbutamol was quite high in the present study,
amounting to 029 l, showing that a dose-related eect of
salbutamol was present in the studied patients. This is likely
to be due to our selection of patients, i.e. needing to show a
dose-related bronchodilation at inclusion. Many broncho-
dilator studies are unable to show dose-related eects of
cumulative doses of drugs. We therefore suggest that
including patients with step-wise improvement in FEV1,
within the doses studied in a randomized stage of the study,
increases the possibility of producing data with dose-related
eects.
We conclude that no or very small dierences in potency
and ecacy between salbutamol Turbuhaler and salbuta-
mol Diskus are present in asthmatic patients. More
importantly, the dierences in therapeutic ratio of these
treatments are minimal, or non-existent.References
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